Listed by the USPTO as HASAN, KHALEDA B
Tech Center 1600 • Art Units: 1636 1646
This examiner grants 59% of resolved cases
HASAN, KHALEDA B works in Tech Center 1600 and Art Unit 1636. The profile records 135 resolved cases, a 59.3% allowance rate, and a median of 1262 days to allowance. Allowance occurred in a modest majority of recorded cases, while the median indicates a lengthy prosecution path.
The interview lift is 49.0%, showing a strong positive association between interviews and allowance. The leading companies are Harbinger Health Inc., Intellia Therapeutics Inc., and Editas Medicine Inc. The listed firms are GOODWIN PROCTER LLP, McNeill PLLC, and Clark+Elbing LLP - Moderna. Counsel may give interviews substantial attention when developing a plan to address prosecution obstacles.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19630254 | Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent | Non-Final OA | Intellia Therapeutics, Inc. |
| 17735929 | Methods and Compositions for Directed Genome Editing | Non-Final OA | Intellia Therapeutics, Inc. |
| 18104461 | GENOME EDITING SYSTEMS COMPRISING REPAIR-MODULATING ENZYME MOLECULES AND METHODS OF THEIR USE | Non-Final OA | Editas Medicine, Inc. |
| 18543930 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | Non-Final OA | ModernaTX, Inc. |
| 18519589 | SOLID PHASE NEGATIVE ENRICHMENT | Non-Final OA | Harbinger Health, Inc. |
| 18385649 | BODILY FLUID TARGET ENRICHMENT | Non-Final OA | Harbinger Health, Inc. |
| 18131634 | SOLID PHASE NEGATIVE ENRICHMENT | Non-Final OA | Harbinger Health, Inc. |
| 18121328 | BODILY FLUID TARGET ENRICHMENT | Non-Final OA | Harbinger Health, Inc. |
| 18057359 | EXOSOMES COMPRISING THERAPEUTIC POLYPEPTIDES | Non-Final OA | Oxford University Innovation Limited |
| 18516247 | ENGINEERED MEGANUCLEASES THAT TARGET HUMAN MITOCHONDRIAL GENOMES | Non-Final OA | University of Miami |
| 18015398 | LIPID NANOPARTICLES FOR DELIVERING THERAPEUTICS TO LUNGS | Non-Final OA | GENEVANT SCIENCES GMBH |
| 18612893 | NUCLEIC ACID SENSOR AGONIST COMPOSITIONS AND USES THEREOF | Non-Final OA | HDT Bio Corp. |
| 18006555 | LIPID NANOPARTICLE COMPRISING MODIFIED NUCLEOTIDES | Final Rejection | STRAND THERAPEUTICS INC. |
| 18418226 | T7 DNA Ligase Variants Having Increased Ligation Efficiency | Non-Final OA | AbClonal Science, Inc. |
| 17701325 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN B (APOB) GENE EXPRESSION | Final Rejection | Sepia Therapeutics Inc. |
| 18554417 | DNA Binding Proteins for Regulating Gene Expression | Non-Final OA | Altius Institute for Biomedical Sciences |
| 17930705 | SYSTEMS AND METHODS FOR DETECTING TUMOR DNA IN MAMMALIAN BLOOD | Non-Final OA | Gene Solutions Joint Stock Company |
| 16547019 | METHODS FOR DELIVERING GENE EDITING REAGENTS TO CELLS WITHIN ORGANS | Final Rejection | BLUEALLELE, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy59.3% of resolved applications examined by Khaleda B Hasan were allowed (135 resolved cases), compared with 37.1% across Art Unit 1636 over the last five years.
This examiner's interview lift is +49.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Khaleda B Hasan took 1,262 days on average from filing to allowance.
Khaleda B Hasan examines applications in Art Unit 1636 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
